NeuroNEXT at SNI

NeuroNEXT at SNI

NeuroNEXT at Swedish Neuroscience Institute is the Pacific Northwest site for a nationwide consortium of 25 centers that will conduct clinical trials for patients with diseases of the nervous system. The NeuroNEXT consortium is sponsored by the National Institute of Neurological Disorders and Stroke.

NeuroNEXT News

August 23, 2012 - First Network Study Underway: Spinal Muscular Atrophy (SMA) Biomakers in the Immediate Postnatal Period of Developement. For more information contact us at

August 22, 2012-NeuroNeighborhood Leadership Forum, Inaugural Gathering: NeuroNEXT at SNI Principle Investigator Dr. John Henson, together with leaders from Viket Medical Corp and the Allen Institute for Brain Science, hosted the first NeuroNeighborhood Leadership Forum, the goal of which is to is to develop a shared vision of funding opportunities, government initiatives, collaborations, and information resources to promote advances in therapeutic neurotechnology. Executives from over 25 organizations from British Columbia to Oregon were in attendance.

August, 2012-Dr. John Henson appointed Chair of the NeuroNEXT Industry Outreach Committee: This committee will aid NeuroNEXT’s aim to bring new treatments to patients by building collaborative relationships with neurotechnology companies.

March 28, 2012. Representatives from 43 local biotechnology companies attended the NeuroNEXT at SNI outreach event on March 28th. The event was co-sponsored by Dr. John Henson, NeuroNEXT at SNI Program Director and the Washington Biotechnology and Biomedical Association. Attendees learned how their organizations can partner with NeuroNEXT at SNI to further the mission of the NeuroNEXT consortium. Speakers included Chris Rivera, President, WBBA, and SNI physicians Marc Mayberg, MD, Ryder Gwinn, MD and John Henson, MD. Attendees also had the opportunity to participate in an informative question and answer session with Dr. Elizabeth McNeil, Scientific Program Director for NeuroNEXT, National Institute of Neurological Disorders and Stroke. To view photos from this evenings event, click on the photo below.


November 18, 2011.  The first meeting of NeuroNEXT consortium members was held at the NIH  on November 18. The consortium launch meeting was attended by an overflow group of investigators, research coordinators and institutional review board officers. Organizational structure and study plans were discussed in detail.  SNI team members John Henson, Megan Alexander, and Estela Hamblen attended the conference.

Clinical Trials Information

The first NeuroNEXT clinical study will investigate spinal muscular atrophy in pediatric patients, and will identify biomarkers to improve diagnostic testing and track disease progression. To be notified when this study is enrolling patients, please complete the affiliate form at the bottom of this page. Other, non-NeuroNEXT studies currently underway in the Pacific Northwest can be identified through

Contact Us

NeuroNEXT at Swedish Neuroscience Institute is led by Associate Chief Medical Director and Director of Neurology, John W. Henson, MD, FAAN. Megan Alexander is the study coordinator. For more information, email or call 206-320-4355.  You can find more information about the NeuroNext consortium at

Become a NeuroNEXT Affiliate

NeuroNEXT at Swedish Neuroscience Institute is establishing a network of affiliate neurologists and neurosurgeons to participate in NeuroNEXT studies.  As a NeuroNEXT affiliate, you will receive occasional emails about upcoming clinical trials, especially regarding the need for study subjects. Affiliate status is open to neurologists and neurosurgeons in the Washington, Wyoming, Alaska, Montana, and Idaho regions.

Note: The information in this form will be used only for informational purposes related to the NeuroNEXT consortium and will not be provided to any other party or organization.



NeuroNEXT Signup:

Contact Information

Neuroscience Institute Administrative Office
550 17th Avenue
Suite 500
Seattle, WA 98122
Phone: 206-320-2800
Fax: 206-320-2827
8 a.m. - 4:30 p.m.
Map & Directions